| Date Filed | Type | Description |
| 10/13/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 10/13/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 10/03/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 10/03/2023 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 10/03/2023 |
SC 13D/A
| SILBER ALLAN C reports a 8.8% stake in POINT Biopharma Global Inc. |
| 10/03/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 10/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"AGREEMENT AND PLAN OF MERGER dated as of OCTOBER 2, 2023, among ELI LILLY AND COMPANY, YOSEMITE FALLS ACQUISITION CORPORATION and POINT BIOPHARMA GLOBAL INC.",
"TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT , dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation , Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent , and the stockholders of POINT Biopharma Global Inc., a Delaware corporation , set forth on Schedule A hereto .  All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement . WHEREAS, as of the date hereof, each Stockholder is the record or beneficial owner of the number of shares of Company Common Stock, Company PSUs and Company Stock Options set forth opposite such Stockholder’ s name on Schedule A ; WHEREAS...",
"TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT , dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation , Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent , and the stockholders of POINT Biopharma Global Inc., a Delaware corporation , set forth on Schedule A hereto .  All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement . WHEREAS, as of the date hereof, each Stockholder is the record or beneficial owner of the number of shares of Company Common Stock, Company PSUs and Company Stock Options set forth opposite such Stockholder’ s name on Schedule A ; WHEREAS...",
"Schedule A",
"Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies" |
|
| 08/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 06/05/2023 |
4
| HOGUE GERALD L. (Director) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 44,749 options to buy
@ $9.12, valued at
$408.1k
|
|
| 06/05/2023 |
4
| GOODMAN JONATHAN R. (Director) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 44,749 options to buy
@ $9.12, valued at
$408.1k
|
|
| 06/05/2023 |
4
| MARGOLIN YAEL (Director) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 44,749 options to buy
@ $9.12, valued at
$408.1k
|
|
| 06/05/2023 |
4
| Malik Rajesh (Director) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 44,749 options to buy
@ $9.12, valued at
$408.1k
|
|
| 06/05/2023 |
4
| Lubner David Charles (Director) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 44,749 options to buy
@ $9.12, valued at
$408.1k
|
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/30/2023 |
4
| SILBER ALLAN C (Executive Chairman) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 537,322 options to buy
@ $6.78, valued at
$3.6M
|
|
| 03/30/2023 |
4
| MCCANN JOE A. (CEO) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 692,643 options to buy
@ $6.78, valued at
$4.7M
|
|
| 03/30/2023 |
4
| KELLY JUSTYNA (COO) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 98,358 options to buy
@ $6.78, valued at
$666.9k
|
|
| 03/30/2023 |
4
| JENSEN JESSICA D. (EVP Clinical Development) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 136,055 options to buy
@ $6.78, valued at
$922.5k
|
|
| 03/30/2023 |
4
| FLESHNER NEIL E. (Chief Medical Officer) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 84,257 options to buy
@ $6.78, valued at
$571.3k
|
|
| 03/30/2023 |
4
| DEMERS WILLIAM L. (CFO) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Granted 131,355 options to buy
@ $6.78, valued at
$890.6k
|
|
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
4
| HOGUE GERALD L. (Director) has filed a Form 4 on POINT Biopharma Global Inc.|
Txns:
| Exercised 17,936 options to buy
@ $6.97, valued at
$125k
|
|
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 8.7% stake in POINT Biopharma Global Inc. |
| 02/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 5.1% stake in POINT Biopharma Global Inc. |
| 11/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|